Proteasome Activity and Immunosenescence
The proteasome is the main proteolytic system implicated in the removal of oxidatively damaged proteins, general turnover of intracellular proteins and targeted degradation of proteins that have been marked by poly-ubiquitination. Impairment of proteasome function has been associated with cellular aging in a variety of tissues and cell types including lymphocytes, and is believed to contribute to the age-related accumulation of oxidized proteins due to their decreased elimination by the proteasomal pathway. This chapter first summarizes the most relevant features of the proteasomal system and then expands on the current knowledge on the impact of aging on proteasome structure and function, taking in account the fate of proteasome upon oxidative stress situations. Finally, the possible implication of age-related alterations of the proteasomal system in the process of immunosenescence is presented.
Unable to display preview. Download preview PDF.
- Chondrogianni N, Stratford FL, Trougakos IP, Friguet B, Rivett AJ, Gonos ES (2003) Central role of the proteasome in senescence and survival of human fibroblasts: induction of a senescencelike phenotype upon its inhibition and resistance to stress upon its activation. J Biol Chem 278:28026–28037PubMedCrossRefGoogle Scholar
- Farout L, Mary J, Vihn J, Szweda LI, Friguet B (2006). Inactivation of the Proteasome by 4- Hydroxy-2-nonenal is site specific and dependant on 20S proteasome subtypes. Arch Biochem Biophys (in press)Google Scholar
- Finley D, Ciechanover A, Varshavsky A (2004) Ubiquitin as a central cellular regulator. Cell 116: S29–S32, 2 p following S32Google Scholar
- Friguet B, Stadtman ER, Szweda LI (1994a) Modification of glucose-6-phosphate dehydrogenase by 4-hydroxy-2-nonenal. Formation of cross-linked protein that inhibits the multicatalytic protease. J Biol Chem 269:21639–21643Google Scholar
- Furet P, Imbach P, Noorani M, Koeppler J, Laumen K, Lang M, Guagnano V, Fuerst P, Roesel J, Zimmermann J, Garcia-Echeverria C (2004). Entry into a new class of potent proteasome inhibitors having high antiproliferative activity by structure-based design. J Med Chem 47:4810–4813PubMedCrossRefGoogle Scholar
- Koguchi Y, Kohno J, Nishio M, Takahashi K, Okuda T, Ohnuki T, Komatsubara S (2000) TMC-95A, B, C, and D, novel proteasome inhibitors produced by Apiospora montagnei Sacc. TC 1093. Taxonomy, production, isolation, and biological activities. J Antibiot (Tokyo) 53:105–109Google Scholar
- Meidenbauer N, Zippelius A, Pittet MJ, Laumer M, Vogl S, Heymann J, Rehli M, Seliger B, Schwarz S, Le Gal FA, Dietrich PY, Andreesen R, Romero P, Mackensen A (2004) High frequency of functionally active Melan-a-specific T cells in a patient with progressive immunoproteasome- deficient melanoma. Cancer Res 64:6319–6326PubMedCrossRefGoogle Scholar